Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.

Repare Therapeutics Inc.

Repare Therapeutics Inc ( ($RPTX) ) has released its Q3 earnings. Here is a breakdown of the information Repare Therapeutics Inc presented to its i...

Repare Therapeutics Reports Positive Q3 2025 Results

An update from Repare Therapeutics ( ($RPTX) ) is now available. Repare Therapeutics Inc. has entered into an Arrangement Agreement with XenoTherap...

Repare Therapeutics Announces Acquisition by XenoTherapeutics

Repare Therapeutics received a Hold rating and price target from TD Cowen analyst Marc Frahm today. According to TipRanks, Frahm is a 5-star analys...

Market Cap	$92.85M	P/E Ratio	N/A
52W High	$2.30	52W Low	$0.89
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	10.9%	52W Position	88.7%
Overall Score	64	Value Score	60
Quality Score	42	Technical Score	91

EPS Current Est	$-1.73	EPS Next Est	$-1.26
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RPTX	$2.14	0.00%	849.39K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RPTX	$2.14	0%	849.39K
3
4
5
6

RPTX

RPTX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Repare Therapeutics Inc. Data in Excel

Get Repare Therapeutics Inc. Data in Excel